Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Baudax Bio Inc is a biotechnology business based in the US. Baudax Bio Inc shares (BXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Baudax Bio Inc employs 80 staff and has a trailing 12-month revenue of around $1.4 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $0.26 |
|---|---|
| 52-week range | $0.25 - $22.40 |
| 50-day moving average | $0.57 |
| 200-day moving average | $2.91 |
| Wall St. target price | $2.00 |
| PE ratio | 0.0985 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $2.59 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.255 from 2022-09-27
| 1 week (2022-09-21) | -8.93% |
|---|---|
| 1 month (2022-08-29) | -53.25% |
| 3 months (2022-06-29) | -69.27% |
| 6 months (2022-03-29) | -85.91% |
| 1 year (2021-09-29) | -55.43% |
|---|---|
| 2 years (2020-09-29) | -90.89% |
| 3 years (2019-09-25) | N/A |
| 5 years (2017-09-25) | N/A |
Valuing Baudax Bio Inc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Baudax Bio Inc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Baudax Bio Inc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Baudax Bio Inc shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $1.4 million |
|---|---|
| Gross profit TTM | $-1,365,000 |
| Return on assets TTM | -51.7% |
| Return on equity TTM | -358.12% |
| Profit margin | 0% |
| Book value | $0.52 |
| Market capitalisation | $2.1 million |
TTM: trailing 12 months
We're not expecting Baudax Bio Inc to pay a dividend over the next 12 months.
Baudax Bio Inc's shares were split on a 1:35 basis on 15 February 2022. So if you had owned 35 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Baudax Bio Inc shares – just the quantity. However, indirectly, the new 3400% higher share price could have impacted the market appetite for Baudax Bio Inc shares which in turn could have impacted Baudax Bio Inc's share price.
Over the last 12 months, Baudax Bio Inc's shares have ranged in value from as little as $0.25 up to $22.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Baudax Bio Inc's is 1.687. This would suggest that Baudax Bio Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Baudax Bio, Inc. , a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania. .
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.